Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
What the trials showed In the phase 2 trial, injection site reactions with cagrilintide occurred at dramatically higher rates than placebo
Stabilization of TRI sustains pathway activity, promotes CSC-like phenotypes, and confers resistance to TKIs such as regorafenib in HCC
Its phase 2 results were published in The Lancet and presented at ObesityWeek 2025, and Eli Lilly stated phase 3 enrolment was planned to begin by the end of 2025
How it works: MOTS-C is a naturally occurring mitochondrial peptide discovered at USC in 2015
Looking ahead, the future of therapeutic peptides is promising
US$ 25.34
US$ 24.03
US$ 21.58
US$ 24.42
